Detalhe da pesquisa
1.
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis.
N Engl J Med
; 390(6): 497-509, 2024 02 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-38324483
2.
Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH.
N Engl J Med
; 389(11): 998-1008, 2023 Sep 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-37356033
3.
A randomized, double-blind, placebo-controlled trial of aldafermin in patients with NASH and compensated cirrhosis.
Hepatology
; 79(3): 674-689, 2024 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37732990
4.
A global action agenda for turning the tide on fatty liver disease.
Hepatology
; 79(2): 502-523, 2024 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37540183
5.
Global survey of stigma among physicians and patients with nonalcoholic fatty liver disease.
J Hepatol
; 80(3): 419-430, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-37984709
6.
Can Nonalcoholic Steatohepatitis Be Surgically Cured?: Liver Histologic Comparison After Metabolic Surgery Versus Usual Care.
Ann Surg
; 279(2): 276-282, 2024 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37212393
7.
A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH.
N Engl J Med
; 385(17): 1547-1558, 2021 10 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-34670042
8.
Degree of Discordance Between FIB-4 and Transient Elastography: An Application of Current Guidelines on General Population Cohort.
Clin Gastroenterol Hepatol
; 2024 Feb 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-38428706
9.
Cenicriviroc Lacked Efficacy to Treat Liver Fibrosis in Nonalcoholic Steatohepatitis: AURORA Phase III Randomized Study.
Clin Gastroenterol Hepatol
; 22(1): 124-134.e1, 2024 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37061109
10.
Machine learning models are superior to noninvasive tests in identifying clinically significant stages of NAFLD and NAFLD-related cirrhosis.
Hepatology
; 77(2): 546-557, 2023 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35809234
11.
Safety, pharmacokinetics and pharmacodynamics of obeticholic acid in subjects with fibrosis or cirrhosis from NASH.
Liver Int
; 44(4): 966-978, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38293761
12.
Cardiovascular disease risk in paediatric and young adult non-alcoholic fatty liver disease.
Gut
; 72(3): 573-580, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36522149
13.
Hepatic and renal improvements with FXR agonist vonafexor in individuals with suspected fibrotic NASH.
J Hepatol
; 78(3): 479-492, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36334688
14.
A global research priority agenda to advance public health responses to fatty liver disease.
J Hepatol
; 79(3): 618-634, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37353401
15.
Artificial Intelligence Applications in Hepatology.
Clin Gastroenterol Hepatol
; 21(8): 2015-2025, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37088460
16.
MRI-AST (MAST) Score Accurately Predicts Major Adverse Liver Outcome, Hepatocellular Carcinoma, Liver Transplant, and Liver-Related Death.
Clin Gastroenterol Hepatol
; 21(10): 2570-2577.e1, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-36813013
17.
Disease State Transition Probabilities Across the Spectrum of NAFLD: A Systematic Review and Meta-Analysis of Paired Biopsy or Imaging Studies.
Clin Gastroenterol Hepatol
; 21(5): 1154-1168, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35933075
18.
Performance of Noninvasive Tests of Fibrosis Among Asians, Hispanic, and non-Hispanic Whites in the STELLAR Trials.
Clin Gastroenterol Hepatol
; 21(1): 90-102.e6, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35074532
19.
The use of current knowledge and non-invasive testing modalities for predicting at-risk non-alcoholic steatohepatitis and assessing fibrosis.
Liver Int
; 43(5): 964-974, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36864668
20.
MRI-based (MAST) score accurately identifies patients with NASH and significant fibrosis.
J Hepatol
; 76(4): 781-787, 2022 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-34798176